CN Bio Launches PhysioMimix® Bioavailability Assay Kit: Human 18

CN Bio has unveiled the PhysioMimix® Bioavailability Assay Kit: Human 18, a groundbreaking innovation for preclinical drug development. Designed for use with the PhysioMimix Multi-organ System, this easy-to-use kit bridges the gap between in vitro and in vivo studies, enabling researchers to generate accurate, predictive data on human oral bioavailability earlier in the drug development pipeline.

Revolutionizing Bioavailability Prediction

The PhysioMimix Bioavailability Assay Kit addresses a long-standing challenge in preclinical workflows: the need for more accurate, human-relevant bioavailability data. By fluidically linking CN Bio’s FDA-recognized Liver-on-a-Chip with Altis Biosystems’ RepliGut® Jejunum model, the system replicates intestinal absorption, metabolism, and hepatic clearance.

Key features include:

• Dual Dosing Routes: Supports both intravenous and oral dosing simulations.
• Enhanced Predictive Power: Provides human-relevant insights unavailable from traditional in vitro or animal models.
• Streamlined Assay Setup: An all-in-one solution that minimizes the burden of assay development and validation.
• Scalable Testing: Delivers up to 18 replicates per kit for comprehensive candidate profiling.

This innovative solution empowers researchers to optimize lead selection, improve in vivo study designs, and reduce reliance on animal testing.